Trial finds weight loss drug taken monthly helps people lose 20% of body weight - The new drug may rival other weight loss ...

Research out today is the latest to suggest that semaglutide can significantly lower people's risk of dementia.

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

Bio Inc (NASDAQ:IBIO) shares jumped 50% following the announcement of preclinical results showing its engineered amylin ...

Mean body weight reductions after 24 weeks ranged from 8.2% to 10.3% in the MDR-001 cohorts, versus 2.5% in the placebo arm.